DSA
List 5 signs and symptoms and EOE patients may experience
Dysphagia, chest pain, fibrosis, food impaction, and impaired quality of life
What are 2 known triggers?
Food allergens and aeroallergens
List the % of histologic remission for the Dupixent only arm in both part A-C and B-C
A-C = 56% and B-C = 85%
How many pediatric patients were involved in parts A & B of the clinical trial?
72 patients (Part 20/Part B 52)
What are the treatment goals of EOE?
clinical, endoscopic and histologic remission
What are the 3 symptoms resulting in EOE?
dysphagia, food impaction and painful swallowing
What was the point reduction in EREFs score from baseline with Dupixent for parts A and A-C?
A = -3.2 and A-C = -4.1
What is the difference between the safety profile from the MVA and the 52-week reprint carrier?
>2% vs >10, in addition, they expanded on the symptoms for upper respiratory tract infection and injection site reaction
List 5 current EOE management approaches
PPIs, dilation, STC, food elimination and EGD
What are the pathophysiological effects of EOE?
eosinophilic inflammation, epithelial barrier dysfunction, endoscopic features and esophageal dysfunction
What is the absolute change in DSQ score at week 52 for Part B-C in the placebo/Dupixent arm?
-27.3 (78%)
In the reprint carrier, Part A-C, how many patients discontinued the placebo/Dupixent?
2 patients/5%
The HCP is not familiar with Type 2 Inflammation and the role it plays in EOE
Verbalize the inflammatory cascade and reference the signs and symptoms
HCP wants to know specifically the MOA of Dupixent
Using the MVA, verbalize the MOA diagram and how Dupixent plays a role
HCP wants to know how long a patient needs stay on Dupixent
Using the MVA, verbalize the results of 24 &52 week co-primary/secondary endpoints
The HCP is asking about Dupixent being a biologic and the side effects that go along with it
Using the MOA, verbalize the safety profile and the important safety consideration